Modelling glioblastoma resistance to temozolomide. A mathematical model to simulate cellular adaptation in vitro

被引:1
|
作者
Pérez-Aliacar, Marina [1 ,2 ]
Ayensa-Jiménez, Jacobo [2 ,3 ]
Ranđelović, Teodora [3 ,4 ]
Ochoa, Ignacio [2 ,3 ,4 ]
Doblaré, Manuel [2 ,3 ,4 ,5 ]
机构
[1] Mechanical Engineering Department, School of Engineering and Architecture, University of Zaragoza, C/ Maria de Luna, Zaragoza,50018, Spain
[2] Engineering Research Institute of Aragón (I3A), University of Zaragoza, C/ Mariano Esquillor, Zaragoza,50018, Spain
[3] Institute for Health Research Aragón (IIS Aragón), Avda. San Juan Bosco, Zaragoza,50009, Spain
[4] Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Spain
[5] Nanjing Tech University, China
关键词
Chemotherapy - Diagnosis - Diseases - Patient monitoring - Sensitivity analysis;
D O I
10.1016/j.compbiomed.2024.108866
中图分类号
学科分类号
摘要
Drug resistance is one of the biggest challenges in the fight against cancer. In particular, in the case of glioblastoma, the most lethal brain tumour, resistance to temozolomide (the standard of care drug for chemotherapy in this tumour) is one of the main reasons behind treatment failure and hence responsible for the poor prognosis of patients diagnosed with this disease. In this work, we combine the power of three-dimensional in vitro experiments of treated glioblastoma spheroids with mathematical models of tumour evolution and adaptation. We use a novel approach based on internal variables for modelling the acquisition of resistance to temozolomide that was observed in experiments for a group of treated spheroids. These internal variables describe the cell's phenotypic state, which depends on the history of drug exposure and affects cell behaviour. We use model selection to determine the most parsimonious model and calibrate it to reproduce the experimental data, obtaining a high level of agreement between the in vitro and in silico outcomes. A sensitivity analysis is carried out to investigate the impact of each model parameter in the predictions. More importantly, we show how the model is useful for answering biological questions, such as what is the intrinsic adaptation mechanism, or for separating the sensitive and resistant populations. We conclude that the proposed in silico framework, in combination with experiments, can be useful to improve our understanding of the mechanisms behind drug resistance in glioblastoma and to eventually set some guidelines for the design of new treatment schemes. © 2024
引用
收藏
相关论文
共 43 条
  • [41] In-silico model of skin penetration based on experimentally determined input parameters. Part II: Mathematical modelling of in-vitro diffusion experiments. Identification of critical input parameters
    Naegel, Arne
    Hansen, Steffi
    Neumann, Dirk
    Lehr, Claus-Michael
    Schaefer, Ulrich F.
    Wittum, Gabriel
    Heisig, Michael
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 68 (02) : 368 - 379
  • [42] Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression (vol 12, pg 727, 2010)
    Le Calve, B.
    Rynkowski, M.
    Le Mercier, M.
    Bruyere, C.
    Lonez, C.
    Gras, T.
    Haibe-Kains, B.
    Bontempi, G.
    Decaestecker, C.
    Ruysschaert, J-M
    Kiss, Robert
    Lefranc, Florence
    NEOPLASIA, 2011, 13 (09):
  • [43] In-silico model of skin penetration based on experimentally determined input parameters. Part II: Mathematical modelling of in-vitro diffusion experiments. Identification of critical input parameters (vol 68, pg 368, 2008)
    Naegel, Arne
    Hansen, Steffi
    Neumann, Dirk
    Lehr, Claus-Michael
    Schaefer, Ulrich F.
    Wittum, Gabriel
    Heisig, Michael
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 68 (03) : 846 - 846